Skip to main content

Advertisement

SpringerLink
Log in

Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The aim of this study was to assess the responsiveness to change of the quality of life evaluated by the EuroQol Five Dimensions Questionnaire (EQ-5D) and Hospital Anxiety and Depression Scale (HADS) after biological treatment in a population of rheumatoid arthritis patients. A cohort of patients with RA (n = 29) treated with tocilizumab (TCZ) were analyzed in the study. The inclusion criteria were patients aged between 18 and 65 years, fulfilling American College of Rheumatology 1987 criteria for RA. All patients had inadequate response to methotrexate and with no prior biologic exposure. They were evaluated clinically including Disease Activity Score 28 (DAS28), and the European Quality of Life 5 Dimensions (EQ-5D) to measure the quality of life, and HAD assessed the anxiety and depression status at the initiation of treatment with anti-IL 6 receptor antibody agent and after 6 months. Sensitivity to change was quantified by the effect size (ES) before and after the treatment with TCZ. Among 29 patients with RA included in the study, 25 were females and 4 males. The mean age was 42 years ± 13.4 (SD). Three patients were excluded from the study before 24 weeks because of serious side effects, and five have missing data. The study population exhibited significant decreases in all measures of disease activity at 24 weeks. Physical activity expressed by the Health Assessment Questionnaire (HAQ) score increased through the observation period (for all p < 0.001). Sensitivity to change was high for the VAS and EQ-5D (ES 1.58 and 1.36, respectively) but only moderate for the HAD anxiety component (ES = 0.70) and small for the HAD depression component (ES = 0.4). The EQ-5D and VAS were more responsive than HADS to evaluate the quality of life on patient with RA treated with TCZ.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kingsley G et al (2011) Quality of life and the outcome of established rheumatoid arthritis. Best Pract Res Clin Rheumatol 25:585–606

    Article  PubMed  Google Scholar 

  2. Marshall S et al (2006) Impact of patient-reported outcome measures on routine practice: a structured review. J Eval Clin Pract 12:559–68

    Article  PubMed  Google Scholar 

  3. Van Vollenhoven R et al (2009) Health assessment questionnaire-disability index (haq-di) scores in patients with rheumatoid arthritis (ra) treated with tocilizumab plus conventional anti-rheumatic drugs. Value Health 12(7):A434

    Article  Google Scholar 

  4. Zigmond AS et al (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361–70

    Article  CAS  PubMed  Google Scholar 

  5. Bjelland I et al (2002) The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 52:69–77

    Article  PubMed  Google Scholar 

  6. El-Rufaie OE (1987) Validity study of the Hospital Anxiety and Depression Scale among a group of Saudi patients. Br J Psychiatry 151:687–8

    Article  CAS  PubMed  Google Scholar 

  7. El-Rufaie OE (1995) Retesting the validity of the Arabic version of the Hospital Anxiety and Depression (HAD) Scale in primary health care. Soc Psychiatry Psychiatr Epidemiol 30(1):26–31

    Article  CAS  PubMed  Google Scholar 

  8. Räsänen P et al (2006) Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int J Technol Assess Health Care 22:235–241

    Article  PubMed  Google Scholar 

  9. Brettschneider C et al (2013) Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with somatoform disorders. Health Qual Life Outcome 11:3

    Article  Google Scholar 

  10. Prieto L. e al. (2004) What is the value of social value?. BMC Med Resh Methodol 4

  11. Schweikert B et al (2006) Validation of the EuroQol questionnaire in cardiac rehabilitation. Heart 92:62–67

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Kim MH et al (2005) Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases. Qual Life Res 14:1401–1406

    Article  PubMed  Google Scholar 

  13. Luo N et al (2003) Validity and reliability of the EQ-5D self-report questionnaire in English-speaking Asian patients with rheumatic diseases in Singapore. Qual Life Res 12:87–92

    Article  CAS  PubMed  Google Scholar 

  14. Lang HC et al (2010) Validation of EQ-5D in patients with cervical cancer in Taiwan. Support Care Cancer 18:1279–1286

    Article  PubMed  Google Scholar 

  15. Khoudri I et al (2012) Measuring quality of life after intensive care using the Arabic version for Morocco of the EuroQol 5 Dimensions. BMC Res Notes 5:56

    Article  PubMed Central  PubMed  Google Scholar 

  16. Aburuz S (2009) The validity and reliability of the Arabic version of the EQ-5D: a study from Jordan. Ann Saudi Med 29(4):304–308

    Article  PubMed Central  PubMed  Google Scholar 

  17. Aissaoui Y et al (2005) Validation of a behavioral pain scale in critically ill, sedated, and mechanically ventilated patients. Anesth Analg Crit Care Trauma 101:1470–6

    Article  Google Scholar 

  18. Wright JG et al (1997) A comparison of different indices of responsiveness. J Clin Epidemiol 50:239–47

    Article  CAS  PubMed  Google Scholar 

  19. Angst F (2008) Responsiveness of five condition-specific and generic outcome assessment instruments for chronic pain. BMC Med Res Methodol 8:26

    Article  PubMed Central  PubMed  Google Scholar 

  20. Strand V et al (2012) Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology 51:1860–1869

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Buitinga L et al (2012) Responsiveness of the EQ-5D and SF-6D in RA Patients. Arthritis Care Res 64:6

    Article  Google Scholar 

  22. Gaujoux-Viala C et al (2011) La comparaison de la sensibilité au changement de l’EQ-5D et du SF-6D chez les patients souffrant d’arthrite débutante est en faveur de l’utilisation du SF-6D : résultats de la cohorte française ESPOIR. Rev Epidemiol Sante Publique 59S:S18–S36

    Google Scholar 

  23. Ibn YY et al (2012) Health-related quality of life in Moroccan patients with rheumatoid arthritis. Clin Rheumatol 31(10):1471–7

    Article  Google Scholar 

  24. Kadri N et al (2010) Moroccan national study on prevalence of mental disorders: a community-based epidemiological study. Acta Psychiatr Scand 121(1):71–74

    Article  CAS  PubMed  Google Scholar 

  25. Covic T et al (2009) Variability in depression prevalence in early rheumatoid arthritis: a comparison of the CES-D and HAD-D Scales. BMC Musculoskelet Disord 10:18

    Article  PubMed Central  PubMed  Google Scholar 

  26. Hakkou J et al (2013) Sleep disturbance in Moroccan patients with ankylosing spondylitis: prevalence and relationships with disease-specific variables, psychological status and quality of life. Rheumatol Int 33(2):285–90

    Article  PubMed  Google Scholar 

  27. El-Miedany YM et al (2003) Evaluating changes in health status: sensitivity to change of the modified Arabic health assessment questionnaire in patients with rheumatoid arthritis. Joint Bone Spine 70:1093–1099

    Google Scholar 

  28. El-Miedany YM et al (2002) Is anxiety a more common disorder than depression in rheumatoid arthritis? Joint Bone Spine 69:300–6

    Article  PubMed  Google Scholar 

  29. Kazemi H et al (2013) Anxiety and depression in patients with amputated limbs suffering from phantom pain: a comparative study with non-phantom chronic pain. Int J Prev Med 4(2):218–25

    PubMed Central  PubMed  Google Scholar 

  30. Magni G et al (1994) Prospective study on the relationship between depressive symptoms and chronic musculoskeletal pain. Pain 56:289–97

    Article  CAS  PubMed  Google Scholar 

  31. Covic T et al (2012) Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the Depression, Anxiety and Stress Scale (DASS) and the Hospital, Anxiety and Depression Scale (HADS). BMC Psychiatry 12:26

    Article  Google Scholar 

  32. Uguz F et al (2009) Anti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis. Psychiatry Clin Neurosci 63(1):50–5

    Article  CAS  PubMed  Google Scholar 

  33. World Health Organization (WHO) (2001) ICF—International Classification of Functioning, Disability and Health. World Health Organization, Geneva, Switzerland 10–20

    Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

  1. Faculty of Medicine and Pharmacy, University Med V Souissi, Rabat-Sale, Morocco

    L. Traki, S. Rostom, R. Bahiri & N. Hajjaj-Hassouni

  2. Department of Rheumatology, El Ayachi University Hospital, Rabat-Sale, Morocco

    L. Traki, S. Rostom, R. Bahiri & N. Hajjaj-Hassouni

  3. Faculty of Medicine and Pharmacy, University Sidi Mohammed Ben Abdellah, Fes, Morocco

    L. Tahiri & T. Harzy

  4. Department of Rheumatology, Hassan II Hospital, Fes, Morocco

    L. Tahiri & T. Harzy

  5. Faculty of Medicine and Pharmacy, University Med V-Souissi, Rabat, Morocco

    R. Abouqal

  6. Laboratory of Biostatistical, Clinical and Epidemiological Research (LBRCE), Rabat, Morocco

    R. Abouqal

Authors
  1. L. Traki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Rostom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Tahiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Bahiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Harzy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Abouqal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N. Hajjaj-Hassouni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Traki.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Traki, L., Rostom, S., Tahiri, L. et al. Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab. Clin Rheumatol 33, 1055–1060 (2014). https://doi.org/10.1007/s10067-014-2609-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-014-2609-z

Keywords

Search

Navigation